Skip to content

A Real World Study of Respiratory Critical Disease.

A Real World Study of Respiratory Critical Disease.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07165717
Enrollment
500
Registered
2025-09-10
Start date
2019-03-01
Completion date
2025-12-31
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS (Acute Respiratory Distress Syndrome), Real World Study

Brief summary

Acute Respiratory Distress Syndrome (ARDS) is a form of acute diffuse lung injury caused by various etiologies, which rapidly progresses to acute respiratory failure. It is characterized by a sudden onset and severe clinical course. Globally, ARDS affects approximately 3 million individuals each year, accounting for about 10% of admissions to intensive care units (ICUs). Due to the lack of specific pharmacological therapies, mechanical ventilation remains the mainstay of treatment. Therefore, identifying and analyzing prognostic factors for ARDS patients is of great significance for improving patient outcomes and reducing the incidence of poor prognosis.

Interventions

OTHERNo Intervention: Observational Cohort

Obsercational study

Sponsors

Ming Zhong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with underlying diseases associated with high risk of ARDS, including but not limited to: sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, massive blood transfusion, other high-risk conditions, or other factors causing excessive respiratory drive. * Patients meeting the inclusion criteria for a high-risk ARDS population. * Patients (or legal representatives) who have provided a signed and dated informed consent form.

Exclusion criteria

* Age under 18 years. * HIV infection. * Known immunodeficiency disorders (e.g., leukemia, common variable immunodeficiency, etc.). * History of solid organ or bone marrow transplantation. * Receiving treatment with G-CSF or GM-CSF. * Patients with a decision to withdraw from active treatment.

Design outcomes

Primary

MeasureTime frameDescription
MortalityDay 28 after ARDS diagnosisClinical observation

Secondary

MeasureTime frameDescription
Chest CT ScanMonitored dailyChest CT imaging
Complete Blood CountMonitored dailyBlood sampling and laboratory testing
Serial Arterial Blood Gas MonitoringMonitored daily after enrollmentArterial blood gas collection
Fluid Input and Output BalanceWhenever fluid input or output occursClinical nursing records
Mechanical Ventilation MonitoringEvery second after intubationAutomatically recorded by ventilator

Countries

China

Contacts

Primary ContactYuxian Wang, Doctor
wang.yuxian@zs-hospital.sh.cn86-13482359545

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026